October 18, 2017 11:42 AM ET

Biotechnology

Company Overview of Mesoblast, Inc.

Key Executives for Mesoblast, Inc.

NameBoard RelationshipsTitleAge
Silviu Itescu MBBS (Hons), FRACP, FACP, FACRA12 RelationshipsChief Executive Officer and Executive Director60
Michael Schuster MS, BSc, MBANo RelationshipsCo-Founder and Head of Pharma Partnering--
Paul Hodgkinson MA (Hons), FCANo RelationshipsChief Financial Officer49
John D. McMannis Ph.D.17 RelationshipsHead of Manufacturing61
Paul J. Simmons BSc, Ph.D.No RelationshipsHead of Research and New Product Development58
View More Key Executives

Mesoblast, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Brian Jamieson FCA, MAICD, FAICD 24 RelationshipsSigma Healthcare Limited73
Silviu Itescu MBBS (Hons), FRACP, FACP, FACRA 12 RelationshipsMesoblast Limited60
Donal Paul O’Dwyer BEng, MBA 44 RelationshipsAtCor Medical Holdings Limited64
Robert E. Campbell Ph.D. 37 RelationshipsCenter For Health Value Innovation--
William A. M. Burns BA 66 RelationshipsBioMedPartners AG70
View All Board Members

Mesoblast, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
There is no committee data available.
*Data is at least as current as the most recent Definitive Proxy.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CEO COMPENSATION IN THIS INDUSTRY

  Industry Range
Salary
388.0K
Bonus
241.5K
Total Short Term Compensation
483.3K
Total Value of Options
17.8M
Compensation as of Fiscal Year
Mesoblast, Inc. CEO Compensation
Industry Average

INDUSTRY EXECUTIVE CHANGES

Tissue Regenix Group plc Announces Executive Changes
October 18, 2017 6:00 AM ET
Monash IVF Group Ltd. Announces the Appointment of David Morris as Chief Executive Officer and Managing Director, Effective 13 November 2017
October 17, 2017 10:12 PM ET
Dimerix Limited Appoints Medical Advisory Board
October 17, 2017 9:22 PM ET
Oncopeptides AB Appoints Nomination Committee in Respect of AGM 2018
October 17, 2017 2:00 PM ET
Gilead Sciences, Inc. Announces Promotion of Alessandro Riva to Executive Vice President, Oncology Therapeutics
October 17, 2017 12:30 PM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Mesoblast, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.